A clinical-stage biotech has moved a novel oral obesity drug into Phase 1 human trials, backed by primate data published in Nature Communications showing that simultaneous activation of two melanocortin receptors — MC3R and MC4R — drives meaningful weight loss and reduces food intake. The compound, 710GO, is being developed by Northbrook, Ill.-based Kalohexis and began Phase 1 testing in the second quarter of 2026.
For restaurant and hospitality operators already navigating the consumer behavior shifts triggered by GLP-1 medications like semaglutide, the emergence of a distinct oral mechanism is worth tracking closely. The melanocortin system governs appetite and energy balance through different biological pathways than GLP-1 drugs, and if 710GO advances through clinical trials, it could expand the population of patients on appetite-suppressing therapies — deepening the trend toward smaller portions, lower-calorie menu options, and changed drinking patterns that restaurant operators are already adapting to.
Kalohexis frames its platform around the melanocortin system as a foundation for treating both general obesity and cancer cachexia, the muscle-wasting syndrome associated with cancer that drives involuntary appetite loss. That dual focus signals that the company is positioning its science at both ends of the appetite spectrum — relevant context for operators designing menus for medically complex guests in healthcare foodservice, senior dining, and hotel hospitality settings.
The Nature Communications publication, which examined dual MC3R/MC4R activation in male primates with obesity, provides the peer-reviewed preclinical foundation that typically precedes expanded human testing. Phase 1 trials are early-stage safety and dosing studies, meaning commercial availability remains years away — but the science entering human trials now will inform consumer health trends that operators must plan for on a three-to-five-year horizon. Industry analysts covering beverage industry shifts and low-calorie drink demand have already noted that GLP-1 adoption is compressing average check sizes and alcohol consumption in on-premise venues.
The broader takeaway for the restaurant and hospitality industry is directional: oral obesity medications, if they prove as effective as injectable GLP-1 drugs, could dramatically increase the addressable patient population simply by removing the barrier of injection-based delivery. Greater patient uptake would accelerate changes in how Americans eat out, what they order, and how much they consume — variables that will continue to pressure operators on portion economics, menu design, and beverage attach rates. Staying informed on the clinical pipeline, as Food & Beverage Magazine has covered in its analysis of health trends reshaping consumer demand, is increasingly part of the strategic toolkit for forward-looking operators.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.
